

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH19-003, Advancing Infectious Disease Detection and Response in Senegal; GH19-006, Advancing Infectious Disease Detection and Response in Indonesia; GH19-008, Advancing Infectious Disease Detection and Response in Uganda; GH19-009, Advancing Infectious Disease Detection and Response in Vietnam; GH19-010, Advancing Disease Detection and Response in Nigeria; and GH19-015, Strengthening National Capacity for Malaria Operations Research in Malawi.

Date: April 24, 2019.

Time: 9:00 a.m.–2:00 p.m., EDT.

Place: Teleconference.

Agenda: To review and evaluate grant applications.

FOR FURTHER INFORMATION CONTACT: Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Drive, Atlanta, GA 30329-4027, (404) 639-4796; HShoob@cdc.gov.

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri Berger,

Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2019-04848 Filed 3-14-19; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Docket Number CDC-2019-0015, NIOSH-153-E]

Request for the Technical Review of 10 Draft Skin Notation Assignments and Skin Notation Profiles

AGENCY: National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Request for information and comment.

SUMMARY: The National Institute for Occupational Safety and Health of the Centers for Disease Control and Prevention announces the availability of 10 draft skin notation profile documents now available for public comment entitled:

Skin notation profile: Cyclohexanol

Skin notation profile: Cyclohexanone

Skin notation profile: Cyclonite

Skin notation profile: Diacetyl and 2,3-Pentanedione

Skin notation profile:

Diethylenetriamine

Skin notation profile: beta-Chloroprene

Skin notation profile: Chlorodiphenyl 42% Chlorine

Skin notation profile: Chlorodiphenyl 54% Chlorine

Skin notation profile: Dioxane

Skin notation profile: 2,4-Toluene

diisocyanate, 2,6-Toluene

diisocyanate, and the mixture of 2,4- and 2,6-Toluene diisocyanate

To view the notice and related materials, visit <https://www.regulations.gov> and enter CDC-2019-0015 in the search field and click "Search."

DATES: Electronic or written comments must be received by May 14, 2019.

ADDRESSES: You may submit comments, identified by CDC-2019-0015 and docket number NIOSH-153-E, by any of the following methods:

- *Federal eRulemaking Portal:*

<https://www.regulations.gov>. Follow the instructions for submitting comments.

- *Mail:* National Institute for

Occupational Safety and Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati, Ohio 45226-1998.

Instructions: All information received in response to this notice must include the agency name and docket number [CDC-2019-0015; NIOSH-153-E]. All relevant comments received will be

posted without change to <https://www.regulations.gov>, including any personal information provided. All electronic comments should be formatted as Microsoft Word. For access to the docket to read background documents or comments received, go to <https://www.regulations.gov>. All information received in response to this notice will also be available for public examination and copying at the NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH 45226-1998.

FOR FURTHER INFORMATION CONTACT: Naomi Hudson, NIOSH/EID, Robert A. Taft Laboratories, 1090 Tusculum Avenue, MS-C32, Cincinnati, OH 45226. Telephone: (513) 533-8388 (not a toll free number).

SUPPLEMENTARY INFORMATION: The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) is conducting a public review of the draft skin notations and support technical documents, entitled Skin Notations Profiles, for 10 chemicals. NIOSH is requesting technical reviews of the draft Skin Notation Profiles.

Background: In 2009, NIOSH published Current Intelligence Bulletin (CIB) 61—A Strategy for Assigning New NIOSH Skin Notations [NIOSH 2009-147; <http://www.cdc.gov/niosh/docs/2009-147/pdfs/2009-147.pdf>]. The CIB presents a strategic framework that is a form of hazard identification designed to do the following:

1. Ensure that the assigned skin notations reflect the contemporary state of scientific knowledge.
2. Provide transparency behind the assignment process.

3. Communicate the hazards of chemical exposures of the skin.
4. Meet the needs of health professionals, employers, and other interested parties in protecting workers from chemical contact with the skin.

This strategy involves the assignment of multiple skin notations for distinguishing systemic (SYS), direct (DIR), and sensitizing (SEN) effects caused by exposure of skin (SK) to chemicals.

Information Needs: To facilitate the review of these documents, NIOSH requests that the following questions be taken into consideration:

1. Does this document clearly outline the systemic health hazards associated with exposures of the skin to the chemical? If not, what specific information is missing from the document?

2. If the SYS or SYS (FATAL) notations are assigned, are the rationale

and logic behind the assignment clear? If not assigned, is the logic clear why it was not (e.g., insufficient data, no identified health hazard)?

3. Does this document clearly outline the direct (localized) health hazards associated with exposures of the skin to the chemical? If not, what specific information is missing from the document?

4. If the DIR, DIR (IRR), or DIR (COR) notations are assigned, are the rationale and logic behind the assignment clear? If not assigned, is the logic clear why it was not (e.g., insufficient data, no identified health hazard)?

5. Does this document clearly outline the immune-mediated responses (allergic response) as health hazards associated with exposures of the skin to the chemical? If not, what specific information is missing from the document?

6. If the SEN notation is assigned, are the rationale and logic behind the assignment clear? If not assigned, is the logic clear why it was not (e.g., insufficient data, no identified health hazard)?

7. If the ID (SK) or SK were assigned, are the rationale and logic outlined within the document?

8. Are the conclusions supported by the data?

9. Are the tables clear and appropriate?

10. Is the document organized appropriately? If not, what improvements are needed?

11. Are you aware of any scientific data reported in governmental publications, databases, peer-reviewed journals, or other sources that should be included within this document?

References:

Current Intelligence Bulletin 61: A Strategy for Assigning New NIOSH Skin Notations [<https://www.cdc.gov/niosh/docs/2009-147/>]

Dated: March 11, 2019.

Frank J. Hearl,

Chief of Staff, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention.

[FR Doc. 2019-04794 Filed 3-14-19; 8:45 am]

BILLING CODE 4163-19-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, Office of Public Health Preparedness and Response, (BSC, OPHPR)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Board of Scientific Counselors, Office of Public Health Preparedness and Response, (BSC, OPHPR). This meeting is open to the public, limited only by the space available. The meeting room accommodates up to 80 people. Public participants should pre-register for the meeting as described below.

Members of the public that wish to attend this meeting in person should pre-register by submitting the following information by email, facsimile, or phone (see Contact Person for More Information) no later than 12:00 noon (EDT) on Thursday, April 18, 2019:

- Full Name
- Organizational Affiliation
- Complete Mailing Address
- Citizenship
- Phone Number or Email Address

The public is also welcome to listen to the meeting via Adobe Connect. Pre-registration is required by clicking the links below.

WEB ID April 24, 2019 registration:
<https://adobeconnect.cdc.gov/epvdyo95oxsu/event/registration.html>.

WEB ID April 25, 2019 registration:
<https://adobeconnect.cdc.gov/em35bdp1ivh9/event/registration.html>.

Dial in number: 888-664-9959; Participant code: 9241417 (110 seats).

DATES: The meeting will be held on April 24 2019, 10:30 a.m. to 5:00 p.m., EDT; April 25, 2019, 8:30 a.m. to 3:00 p.m., EDT.

ADDRESSES: Centers for Disease Control and Prevention (CDC), Global Communications Center, Building 19, Auditorium B3, 1600 Clifton Road NE, Atlanta, Georgia 30329.

FOR FURTHER INFORMATION CONTACT: Dometa Ouisley, Office of Science and Public Health Practice, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop D-44, Atlanta, Georgia 30329, Telephone: (404) 639-7450; Fax: (404) 471-8772; Email: OPHPR.BSC.Questions@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: This Board is charged with providing advice and guidance to the Secretary, Department of Health and Human Services (HHS), the Assistant Secretary for Health (ASH), the Director, Centers for Disease Control and Prevention (CDC), and the Director, Office of Public Health Preparedness and Response (OPHPR), concerning strategies and goals for the programs and research within OPHPR, monitoring the overall strategic direction and focus of the OPHPR Divisions and Offices, and administration and oversight of peer review for OPHPR scientific programs. For additional information about the Board, please visit: <http://www.cdc.gov/phpr/science/counselors.htm>.

Matters To Be Considered: The two day agenda will include: Day One of meeting will cover briefings and BSC deliberation on the following topics: (1) OPHPR Updates from Director, (2) OPHPR Interval Updates from Division Directors, (3) Updates on the Global Health Security Agenda, (4) Report from the Biological Agent Containment Working Group (BACWG), and (5) Update on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC).

Day Two of the meeting will cover briefings and BSC deliberation on the following topics: (1) Preparedness Updates and OPHPR Discussion—Liaison Representatives, (2) CDC Public Health Law Program Preparedness and Response, (3) Updates from the OPHPR Office of Policy, Planning, and Evaluation. Agenda items are subject to change as priorities dictate.

The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri Berger,

Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2019-04826 Filed 3-14-19; 8:45 am]

BILLING CODE 4163-19-P